---
title: Find predictors of faster decline
nct_id: NCT07644013
status: RECRUITING
sponsor: Peking University First Hospital
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07644013"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07644013"
last_fetched: "2026-06-13T14:03:14.236Z"
source: "Parkinson's Pathways (curated)"
---
# Find predictors of faster decline

**Goal (in five words):** Find predictors of faster decline

**Official Title:** Clinical Features and Natural History of Multiple System Atrophy: A Prospective Multicenter Registry Study in China

**Trial ID:** [NCT07644013](https://clinicaltrials.gov/study/NCT07644013)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Peking University First Hospital
- **Target Enrollment:** 214 participants
- **Start Date:** 2025-06-01
- **Completion Date:** 2029-12-31
- **Conditions:** Multiple System Atrophy, Parkinson's Disease, Atypical Parkinsonism

## Summary For Families

The goal is to map how multiple system atrophy develops and changes over time in Chinese patients, to find clinical features tied to faster decline or worse outcomes, and to build a long-term patient group for future tests of biological signs and treatments. The study does this by following people at several hospitals, collecting medical records, regular exams and standard symptom scales, tests of blood pressure and other nervous-system functions, brain imaging, lab tests, and biological samples, with in-person and phone visits at set times; researchers will also compare the form with mainly slowed movement to the form with mainly balance and coordination problems. Adults aged 40 to 75 who meet the 2022 diagnostic rules for probable or established multiple system atrophy can join, and people with Parkinson disease or healthy volunteers may be enrolled for comparison. People with other atypical parkinsonian disorders, clear secondary causes of parkinsonism, major conditions that affect autonomic tests, or who cannot give consent are not eligible.

## What This Actually Involves

**Placebo** _(From the protocol)_: This is an observational study, so there is no placebo and no experimental treatment is assigned. Researchers observe and collect information while you continue your usual care.

**Visits** _(Ask the coordinator)_: Ask the coordinator how many in-person visits the study involves, how long each one takes, and over what total period.

**Procedures** _(Ask the coordinator)_: Ask the coordinator what tests and procedures are involved, for example blood draws, scans, or questionnaires, and whether any are uncomfortable or invasive.

**Washout** _(Ask the coordinator)_: Ask the coordinator whether you would need to stop or pause any of your current medications before or during the study (a washout period), and for how long.

**Travel & reimbursement** _(Ask the coordinator)_: Ask the coordinator whether travel, parking, or your time is reimbursed or compensated, and what is covered.

_Fields marked “From the protocol” come from the trial's registry record or quoted protocol text. Fields marked “Ask the coordinator” are not reliably available and should be confirmed directly._

## Eligibility

- **Minimum age:** 40 Years
- **Maximum age:** 75 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria

1. Patients with clinically established or clinically probable multiple system atrophy according to the 2022 Movement Disorder Society diagnostic criteria; or
2. Patients with clinically established or clinically probable Parkinson disease according to the Movement Disorder Society diagnostic criteria; or
3. Healthy controls or controls without hereditary or neurodegenerative diseases who voluntarily agree to participate.
4. Age between 40 and 75 years.
5. Ability to provide informed consent or availability of a legally authorized representative when applicable.

Exclusion Criteria

1. Parkinsonism that cannot be classified as Parkinson disease or multiple system atrophy at the time of evaluation.
2. Clinical suspicion or diagnosis of other atypical parkinsonian syndromes, including progressive supranuclear palsy, dementia with Lewy bodies, or corticobasal syndrome.
3. Secondary parkinsonism due to intracranial space-occupying lesions, normal pressure hydrocephalus, drug-induced parkinsonism, or other identifiable causes.
4. Comorbid diseases that may substantially affect autonomic function, such as diabetic peripheral neuropathy or amyloidosis.
5. Refusal to participate in the study or refusal to undergo routine clinical evaluations for parkinsonian syndromes.
6. Psychiatric or behavioral abnormalities that preclude reliable clinical data collection or scale-based assessment.
```

## Locations (1)

- Peking University First Hospital, Beijing, Beijing Municipality, China _(39.9075, 116.3972)_
  - Yang Zhao — (CONTACT) — (+86)18610320188 — zhaoyang2019@pku.edu.cn

## Central Contacts

- Yunchuang Sun, MD — (CONTACT) — sychuang0805@163.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT07644013*  
*HTML version: https://parkinsonspathways.com/trial/NCT07644013*  
*Source data: https://clinicaltrials.gov/study/NCT07644013*